<p>ICU Medical, Inc.（纳斯达克代码：ICUI - 获取免费报告）在目前覆盖该公司的五家研究机构中获得了 “买入” 的平均推荐，Marketbeat.com 报道。一位研究分析师对该股票给予了卖出评级，两位给予了买入评级，两位给予了强烈买入评级。在过去一年中更新了对该股票覆盖的经纪公司中，12 个月的平均目标价为 169.00 美元。</p>
<p>一些股票分析师最近对 ICUI 股票发布了报告。杰富瑞金融集团在周四的报告中将 ICU Medical 的评级上调至 “强烈买入”。派珀·桑德勒在 4 月 17 日的报告中将 ICU Medical 的目标价从 178.00 美元下调至 163.00 美元，并对该股票给予了 “超配” 评级。华尔街 Zen 在 4 月 18 日的报告中将 ICU Medical 的评级从 “买入” 下调至 “持有”。KeyCorp 在 4 月 27 日的报告中将 ICU Medical 的目标价从 180.00 美元下调至 164.00 美元，并对该股票给予了 “超配” 评级。最后，Weiss Ratings 在 1 月 22 日的报告中重申了对 ICU Medical 股票的 “卖出（d-）” 评级。</p>
<p><strong>获取我们关于 ICUI 的最新报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近修改了对该公司的持股。Bryce Point Capital LLC 在第三季度购买了 ICU Medical 股票的新头寸，价值 586,000 美元。Inscription Capital LLC 在第三季度将其在 ICU Medical 的持股增加了 407.9%。Inscription Capital LLC 现在拥有 8,365 股该医疗器械供应商的股票，价值 1,003,000 美元，在上个季度又购买了 6,718 股。Federated Hermes Inc.在第三季度将其在 ICU Medical 的持股增加了 56.5%。Federated Hermes Inc.现在拥有 290,292 股该医疗器械供应商的股票，价值 34,823,000 美元，在上个季度又购买了 104,798 股。Emerald Mutual Fund Advisers Trust 在第三季度购买了 ICU Medical 股票的新头寸，价值 1,096,000 美元。最后，施罗德投资管理集团在第三季度将其在 ICU Medical 的持股增加了 25.2%。施罗德投资管理集团现在拥有 796,704 股该医疗器械供应商的股票，价值 93,246,000 美元，在上个季度又购买了 160,380 股。对冲基金和其他机构投资者持有该公司 96.10% 的股票。</p>
<h2>ICU Medical 的关键新闻</h2>
<p>以下是本周影响 ICU Medical 的关键新闻：</p>
<ul>
<li>积极情绪：第一季度收益超出预期——ICU 报告每股收益 1.97 美元，超过 1.78 美元的共识预期，收入为 5.258 亿美元，超出预期，显示出运营上的超出，通常会支持股票。ICU Medical（ICUI）第一季度收益和收入超出预期</li>
<li>积极情绪：2026 财年指引略微高于市场预期（每股收益指引为 7.75–8.45 美元，而共识约为 7.74），这降低了未来收益的下行风险，并支持估值扩张。ICU Medical 公布 2026 年第一季度业绩</li>
<li>积极情绪：分析师支持——杰富瑞将 ICU 评级上调至 “强烈买入”，派珀·桑德勒重申其买入评级，带来了额外的买方关注，可能会提升股票。杰富瑞升级/覆盖说明派珀·桑德勒重申买入</li>
<li>中性情绪：投资者材料可用——公司发布了其幻灯片和收益演示，便于深入了解细分趋势和利润驱动因素，但本身并不是立即的价格催化剂。收益电话会议演示</li>
<li>消极情绪：收入和利润压力——收入同比下降约 12-14%，报告的净利润率仍然非常薄弱，这引发了对增长轨迹和收益质量的质疑，尽管每股收益超出预期。季度业绩和会议记录</li>
</ul>
<h2>ICU Medical 股票表现</h2>
<p>纳斯达克 ICUI 的股票在周五开盘价为 123.07 美元。该公司的速动比率为 1.15，流动比率为 2.39，债务与股本比率为 0.60。该股票的市值为 30.8 亿美元，市盈率为 6,156.58，PEG 比率为 1.72，贝塔值为 0.74。该股票的 50 日简单移动平均线为 128.93 美元，200 日简单移动平均线为 138.35 美元。ICU Medical 的 52 周低点为 107.00 美元，52 周高点为 160.29 美元。</p>
<p>ICU Medical（纳斯达克代码：ICUI - 获取免费报告）最后一次发布其收益结果是在 2 月 19 日，星期四。该医疗器械供应商报告本季度每股收益（EPS）为 1.91 美元，超过分析师共识预期的 1.68 美元，超出 0.23 美元。该公司本季度的收入为 5.3594 亿美元，而分析师的预期为 5.4120 亿美元。ICU Medical 的股本回报率为 7.33%，净利润率为 0.03%。该公司的季度收入同比下降 14.1%。在前一年同期，该公司发布的每股收益为 2.11 美元。ICU Medical 已将其 2026 财年的指引设定为每股收益 7.750-8.450 美元。作为一个整体，卖方分析师预测 ICU Medical 在当前财年将发布每股收益 6.31 美元。</p>
<h2>ICU Medical 公司简介</h2>
<p>（获取免费报告）</p>
<p>ICU Medical, Inc 及其子公司开发、制造和销售用于输液治疗、血管通路和生命监护应用的医疗设备。其输液治疗产品包括 MicroClave、MicroClave Clear 和 NanoClave 品牌的无针产品；Neutron 导管通畅设备；ChemoClave 和 ChemoLock 封闭系统转移设备，用于限制有害药物或蒸汽浓度的逸出，阻止环境污染物进入系统，并消除针刺伤害的风险；Tego 无针连接器；Deltec GRIPPER 非穿刺针用于门静脉通路；以及 ClearGuard、SwabCap 和 SwabTip 消毒盖。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票超过 ICU Medical</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNVSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNVSQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何关于此故事的问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 ICU Medical 吗？</h2>
<p>在考虑 ICU Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ICU Medical 并不在名单上。</p>
<p>虽然 ICU Medical 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ICU医疗

<p>ICU Medical, Inc.（纳斯达克代码：ICUI）获得了五家研究公司的平均 “买入” 评级。一位分析师将其评为卖出，另外两位评为买入，另外两位评为强力买入。12 个月的平均目标价为 169 美元。最近的报告显示分析师意见不一，Jefferies 将评级上调至 “强力买入”，而 Piper Sandler 则下调了目标价。机构投资者持有 96.10% 的股份。尽管第一季度的盈利超出预期，但收入同比下降了 12-14%，引发了对增长和利润率的担忧</p>

<p>ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) has been given an average recommendation of &#34;Buy&#34; by the five research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $169.00.</p>
<div class="lb-trans"><p>ICU Medical, Inc.（纳斯达克代码：ICUI - 获取免费报告）在目前覆盖该公司的五家研究机构中获得了 “买入” 的平均推荐，Marketbeat.com 报道。一位研究分析师对该股票给予了卖出评级，两位给予了买入评级，两位给予了强烈买入评级。在过去一年中更新了对该股票覆盖的经纪公司中，12 个月的平均目标价为 169.00 美元。</p>
</div><p>A number of equities analysts recently issued reports on ICUI shares. Jefferies Financial Group upgraded ICU Medical to a &#34;strong-buy&#34; rating in a report on Thursday. Piper Sandler decreased their target price on ICU Medical from $178.00 to $163.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, April 17th. Wall Street Zen cut ICU Medical from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 18th. KeyCorp decreased their target price on ICU Medical from $180.00 to $164.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, April 27th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of ICU Medical in a report on Thursday, January 22nd.</p>
<div class="lb-trans"><p>一些股票分析师最近对 ICUI 股票发布了报告。杰富瑞金融集团在周四的报告中将 ICU Medical 的评级上调至 “强烈买入”。派珀·桑德勒在 4 月 17 日的报告中将 ICU Medical 的目标价从 178.00 美元下调至 163.00 美元，并对该股票给予了 “超配” 评级。华尔街 Zen 在 4 月 18 日的报告中将 ICU Medical 的评级从 “买入” 下调至 “持有”。KeyCorp 在 4 月 27 日的报告中将 ICU Medical 的目标价从 180.00 美元下调至 164.00 美元，并对该股票给予了 “超配” 评级。最后，Weiss Ratings 在 1 月 22 日的报告中重申了对 ICU Medical 股票的 “卖出（d-）” 评级。</p>
</div><p><strong>Get Our Latest Report on ICUI</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 ICUI 的最新报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the business. Bryce Point Capital LLC purchased a new position in shares of ICU Medical during the third quarter valued at $586,000. Inscription Capital LLC grew its holdings in shares of ICU Medical by 407.9% during the third quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier's stock valued at $1,003,000 after buying an additional 6,718 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of ICU Medical by 56.5% during the third quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier's stock valued at $34,823,000 after buying an additional 104,798 shares in the last quarter. Emerald Mutual Fund Advisers Trust purchased a new position in shares of ICU Medical during the third quarter valued at $1,096,000. Finally, Schroder Investment Management Group grew its holdings in shares of ICU Medical by 25.2% during the third quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier's stock valued at $93,246,000 after buying an additional 160,380 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近修改了对该公司的持股。Bryce Point Capital LLC 在第三季度购买了 ICU Medical 股票的新头寸，价值 586,000 美元。Inscription Capital LLC 在第三季度将其在 ICU Medical 的持股增加了 407.9%。Inscription Capital LLC 现在拥有 8,365 股该医疗器械供应商的股票，价值 1,003,000 美元，在上个季度又购买了 6,718 股。Federated Hermes Inc.在第三季度将其在 ICU Medical 的持股增加了 56.5%。Federated Hermes Inc.现在拥有 290,292 股该医疗器械供应商的股票，价值 34,823,000 美元，在上个季度又购买了 104,798 股。Emerald Mutual Fund Advisers Trust 在第三季度购买了 ICU Medical 股票的新头寸，价值 1,096,000 美元。最后，施罗德投资管理集团在第三季度将其在 ICU Medical 的持股增加了 25.2%。施罗德投资管理集团现在拥有 796,704 股该医疗器械供应商的股票，价值 93,246,000 美元，在上个季度又购买了 160,380 股。对冲基金和其他机构投资者持有该公司 96.10% 的股票。</p>
</div><h2>Key ICU Medical News</h2>
<div class="lb-trans"><h2>ICU Medical 的关键新闻</h2>
</div><p>Here are the key news stories impacting ICU Medical this week:</p>
<div class="lb-trans"><p>以下是本周影响 ICU Medical 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Q1 earnings beat — ICU reported $1.97 EPS vs. $1.78 consensus and revenue of $525.8M above estimates, showing an operational beat that typically supports the stock. ICU Medical (ICUI) Tops Q1 Earnings and Revenue Estimates</li>
<li>Positive Sentiment: FY2026 guidance nudged slightly above street expectations (EPS guide of $7.75–$8.45 vs. consensus ~7.74), which reduces downside risk to forward earnings and supports multiple expansion. ICU Medical Announces First Quarter 2026 Results</li>
<li>Positive Sentiment: Analyst support — Jefferies upgraded ICU to &#34;strong-buy&#34; and Piper Sandler reaffirmed its buy rating, bringing additional buy-side attention that can lift the stock. Jefferies upgrade / coverage notePiper Sandler Reaffirms Buy</li>
<li>Neutral Sentiment: Investor materials available — the company released its slide deck and earnings presentation, useful for digging into segment trends and margin drivers but not an immediate price catalyst by itself. Earnings Call Presentation</li>
<li>Negative Sentiment: Revenue and margin pressure — revenue was down ~12–14% year-over-year and the reported net margin remains very thin, which raises questions about growth trajectory and earnings quality despite the EPS beat. Quarterly results and transcript</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度收益超出预期——ICU 报告每股收益 1.97 美元，超过 1.78 美元的共识预期，收入为 5.258 亿美元，超出预期，显示出运营上的超出，通常会支持股票。ICU Medical（ICUI）第一季度收益和收入超出预期</li>
<li>积极情绪：2026 财年指引略微高于市场预期（每股收益指引为 7.75–8.45 美元，而共识约为 7.74），这降低了未来收益的下行风险，并支持估值扩张。ICU Medical 公布 2026 年第一季度业绩</li>
<li>积极情绪：分析师支持——杰富瑞将 ICU 评级上调至 “强烈买入”，派珀·桑德勒重申其买入评级，带来了额外的买方关注，可能会提升股票。杰富瑞升级/覆盖说明派珀·桑德勒重申买入</li>
<li>中性情绪：投资者材料可用——公司发布了其幻灯片和收益演示，便于深入了解细分趋势和利润驱动因素，但本身并不是立即的价格催化剂。收益电话会议演示</li>
<li>消极情绪：收入和利润压力——收入同比下降约 12-14%，报告的净利润率仍然非常薄弱，这引发了对增长轨迹和收益质量的质疑，尽管每股收益超出预期。季度业绩和会议记录</li>
</ul>
</div><h2>ICU Medical Stock Performance</h2>
<div class="lb-trans"><h2>ICU Medical 股票表现</h2>
</div><p>Shares of NASDAQ ICUI opened at $123.07 on Friday. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of 6,156.58, a PEG ratio of 1.72 and a beta of 0.74. The stock's fifty day simple moving average is $128.93 and its 200 day simple moving average is $138.35. ICU Medical has a 52-week low of $107.00 and a 52-week high of $160.29.</p>
<div class="lb-trans"><p>纳斯达克 ICUI 的股票在周五开盘价为 123.07 美元。该公司的速动比率为 1.15，流动比率为 2.39，债务与股本比率为 0.60。该股票的市值为 30.8 亿美元，市盈率为 6,156.58，PEG 比率为 1.72，贝塔值为 0.74。该股票的 50 日简单移动平均线为 128.93 美元，200 日简单移动平均线为 138.35 美元。ICU Medical 的 52 周低点为 107.00 美元，52 周高点为 160.29 美元。</p>
</div><p>ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.68 by $0.23. The business had revenue of $535.94 million for the quarter, compared to analysts' expectations of $541.20 million. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The company's quarterly revenue was down 14.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.11 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts forecast that ICU Medical will post 6.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>ICU Medical（纳斯达克代码：ICUI - 获取免费报告）最后一次发布其收益结果是在 2 月 19 日，星期四。该医疗器械供应商报告本季度每股收益（EPS）为 1.91 美元，超过分析师共识预期的 1.68 美元，超出 0.23 美元。该公司本季度的收入为 5.3594 亿美元，而分析师的预期为 5.4120 亿美元。ICU Medical 的股本回报率为 7.33%，净利润率为 0.03%。该公司的季度收入同比下降 14.1%。在前一年同期，该公司发布的每股收益为 2.11 美元。ICU Medical 已将其 2026 财年的指引设定为每股收益 7.750-8.450 美元。作为一个整体，卖方分析师预测 ICU Medical 在当前财年将发布每股收益 6.31 美元。</p>
</div><h2>ICU Medical Company Profile</h2>
<div class="lb-trans"><h2>ICU Medical 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.</p>
<div class="lb-trans"><p>ICU Medical, Inc 及其子公司开发、制造和销售用于输液治疗、血管通路和生命监护应用的医疗设备。其输液治疗产品包括 MicroClave、MicroClave Clear 和 NanoClave 品牌的无针产品；Neutron 导管通畅设备；ChemoClave 和 ChemoLock 封闭系统转移设备，用于限制有害药物或蒸汽浓度的逸出，阻止环境污染物进入系统，并消除针刺伤害的风险；Tego 无针连接器；Deltec GRIPPER 非穿刺针用于门静脉通路；以及 ClearGuard、SwabCap 和 SwabTip 消毒盖。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than ICU Medical</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 ICU Medical</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNVSQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ICUI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何关于此故事的问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ICU Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ICU Medical 吗？</h2>
</div><p>Before you consider ICU Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 ICU Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ICU Medical 并不在名单上。</p>
</div><p>While ICU Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ICU Medical 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of "Buy" by Analysts

Market Beat

Jefferies Financial

Piper Sandler Cos

科凯国际

Federated Hermes

施罗德投资集团

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

ICU 医疗公司（纳斯达克股票代码：ICUI）被分析师给予 “买入” 的平均评级